Abstract
Androgenetic alopecia (AGA) is the most common type of hair loss disorder and affects both men and women. It is characterized by the progressive miniaturization of hair follicles in androgenetic areas of the scalp resulting in a decrease in hair density. While the number of options for managing AGA has increased over the years, evidence-based information and guidelines are limited. Treatments range from the approved and off-label use of pharmacological agents [including oral 5α-reductase inhibitors (e.g. dutasteride) and vasodilators (e.g. topical minoxidil)] to non-pharmacological treatments (e.g. low-level laser therapy) and emerging investigational therapies (e.g. botulinum toxin).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol. 2011;164(1):5–15.
Saceda-Corralo D, Dominguez-Santas M, Vano-Galvan S, et al. What’s new in therapy for male androgenetic alopecia? Am J Clin Dermatol. 2023;24(1):15–24.
Manabe M, Tsuboi R, Itami S, et al. Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. J Dermatol. 2018;45(9):1031–43.
Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252–8.
Gubelin HW. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–98.
Olsen EA, Hordinksy M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–23.
Bramson HN, Hermann D, Batchelor KW, et al. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282(3):1496–502.
Sobhy N, Aly H, Shafee A, et al. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatol. 2013;4(1):40–5.
Saceda-Corralo D, Moustafa F, Moreno-Arrones ÓM, et al. Mesotherapy with dutasteride for androgenetic alopecia: a retrospective study in real clinical practice. J Drugs Dermatol. 2022;21(7):742–7.
Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2021;164(18):2017–23.
Caserini M, Radicioni M, Leuratti C, et al. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19–27.
Caserini M, Radicioni M, Leuratti C, et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842–9.
Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312–6.
Chandrashekar B, Nandhini T, Vasanth V, et al. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17.
Freund BJ, Schwartz M. Treatment of male pattern baldness with botulinum toxin: a pilot study. Plast Reconstr Surg. 2010;126(5):246–8.
Singh S, Neema S, Vasudevan B. A pilot study to evaluate effectiveness of botulinum toxin in treatment of androgenetic alopecia in males. J Cutan Aesthet Surg. 2017;10(3):163.
Bharti J, Sonthalia S, Patil P, et al. Scalp threading with polydioxanone monofilament threads: a novel, effective and safe modality for hair restoration. J Eur Acad Dermatol Venereol. 2017;31(11):e492–3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and conflict of interest
Adis authors: A. Zhuang-Yan and S. M. Hoy are salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability
Not applicable.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhuang-Yan, A., Hoy, S.M. Manage androgenetic alopecia in men with established options but emerging therapies show promise. Drugs Ther Perspect 39, 292–296 (2023). https://doi.org/10.1007/s40267-023-01011-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-023-01011-2